NCT01812330

Efficacy and Safety Study of Ticagrelor

The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: General Hospital of Chinese Armed Police Forces · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of ticagrelor with clopidogrel

Detailed description

180 elective percutaneous coronary intervention patients with clopidogrel resistance were randomized to three groups, Group 1:received clopidogrel 75mg qd ;Group 2:received clopidogrel 150mg qd ; Group 3:received ticagrelor 90mg bid after PCI.Platelet funtion were tested by flowcytometric vasodilator-stimulated phosphoprotein(VASP) analysis before PCI,and 3days,7days and 1 month after PCI,respectively.The aim of our study is to compare the efficacy and safety of ticagrelor with clopidogrel

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	Clopidogrel	After 600mg loading dose, 75mg or 150mg Qd
DRUG	Ticagrelor	90mg Bid

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-12-01
• Completion: 2016-07-01
• First posted: 2013-03-18
• Last updated: 2015-06-24

Locations

1 site across 1 country: China